NCT05265052 2026-03-11
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
3D Medicines
Phase 2 Not yet recruiting
3D Medicines
M.D. Anderson Cancer Center
University of Miami
Tetra Bio-Pharma
University of Southern California
Mundipharma Research GmbH & Co KG
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Associazione Progetto Oncologia UMAN.A